Drugs / T cell injection targeting CD7 chimeric antigen receptor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04480788 | Nov 2020 → Aug 2022 | ALK-negative anaplastic large cell lymphoma, T lymphoblastic leukemia/lymphoma, T-cell acute lymphoblastic leukemia, angioimmunoblastic T-cell lymphoma +3 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T cell injection targeting CD7 chimeric antigen receptor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04480788 ↗ |
| Modality | Cell therapy | “T cell injection targeting CD7 autologous chimeric antigen receptor” NCT04480788 ↗ |
| Target | CD7 | “targeting CD7” NCT04480788 ↗ |